[HTML][HTML] Dupilumab in persistent asthma with elevated eosinophil levels
…, F Skobieranda, L Wang, S Kirkesseli… - New England journal …, 2013 - Mass Medical Soc
Background Moderate-to-severe asthma remains poorly treated. We evaluated the efficacy
and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the …
and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the …
Single‐and multiple‐dose pharmacokinetics of riluzole in white subjects
…, P Truffinet, M Aubeneau, S Kirkesseli… - The Journal of …, 1997 - Wiley Online Library
Riluzole is a novel neuroprotective agent that has been developed for the treatment of
amyotrophic lateral sclerosis. A series of studies was undertaken to establish its pharmacokinetics …
amyotrophic lateral sclerosis. A series of studies was undertaken to establish its pharmacokinetics …
A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers
AL Liboux, JP Cachia, S Kirkesseli… - The Journal of …, 1999 - Wiley Online Library
The pharmacokinetics and tolerability of the novel antiexcitatory agent, riluzole, were compared
in 18 healthy elderly and 18 healthy gender‐ and weight‐matched young volunteers. All …
in 18 healthy elderly and 18 healthy gender‐ and weight‐matched young volunteers. All …
Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma
…, S Millet, B Miller, S Rohatagi, S Kirkesseli - Journal of allergy and …, 2005 - Elsevier
BACKGROUND: Very late antigen (VLA-4) antagonists have been proposed as potential
therapies for diseases in which cell recruitment and accumulation are causative. Asthma, which …
therapies for diseases in which cell recruitment and accumulation are causative. Asthma, which …
Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo …
…, AJ Muslin, L Hovsepian, S Kirkesseli… - British journal of …, 2021 - Wiley Online Library
Aims SAR247799 is a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 (S1P 1 )
agonist designed to activate endothelial S1P 1 and provide endothelial‐protective properties, …
agonist designed to activate endothelial S1P 1 and provide endothelial‐protective properties, …
First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein …
…, L Hovsepian, AJ Muslin, S Kirkesseli… - British Journal of …, 2021 - Wiley Online Library
Aims SAR247799 is a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 (S1P
1 ) agonist with potential to restore endothelial function in vascular pathologies. …
1 ) agonist with potential to restore endothelial function in vascular pathologies. …
Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects
…, S Rohatagi, C Natarajan, S Kirkesseli… - American journal of …, 2004 - journals.lww.com
RPR749 and its methylated metabolite are orally active and selective adenosine A 1 agonists
that can inhibit lipolysis and lower plasma triglyceride levels in a variety of animal models. …
that can inhibit lipolysis and lower plasma triglyceride levels in a variety of animal models. …
A bridging study of fananserin in schizophrenic patients
JJ Sramek, S Kirkesseli… - …, 1998 - search.proquest.com
Fananserin is a potential antipsychotic compound with high affinity for both D4 and 5-HT2A
receptors, and negligible affinity for D2 receptors. Because the tolerance for antipsychotic …
receptors, and negligible affinity for D2 receptors. Because the tolerance for antipsychotic …
Lack of Correlation between In Vitro Inhibition of CYP3A‐Mediated Metabolism by a PPAR‐γ Agonist and Its Effect on the Clinical Pharmacokinetics of Midazolam, an …
…, Y Luo, R Sidhu, S Kirkesseli - The Journal of …, 2001 - Wiley Online Library
RG 12525 (2‐[[4‐[[2‐(1H‐tetrazole‐5‐ylmethyl)phenyl]meth‐oxy]phenoxy]methyl] quinolone)
is a novel peroxisome proliferator‐activated receptor gamma (PPAR‐γ) agonist. In vitro …
is a novel peroxisome proliferator‐activated receptor gamma (PPAR‐γ) agonist. In vitro …
Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler
S Rohatagi, S Chapel, S Kirkesseli… - American journal of …, 2004 - journals.lww.com
A pharmacoscintigraphic study was conducted to compare the dose deposition of HMR 1031
from the existing nebulizer formulation and the new Ultrahaler device to help determine the …
from the existing nebulizer formulation and the new Ultrahaler device to help determine the …
